Who is sponsoring NCT04988230?

NCT04988230 is sponsored by Nanfang Hospital, Southern Medical University.

What drugs are being tested in NCT04988230?

Interventions in NCT04988230: Time restricted feeding, Continuous Energy Restriction.

What condition does NCT04988230 study?

NCT04988230 studies Nonalcoholic Fatty Liver Disease.

Is NCT04988230 still recruiting?

NCT04988230 is currently completed. Last updated 6 April 2022.

Last reviewed 2022-04-06 · How we verify

NCT04988230: TREATY-FLD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Time Restricted Feeding on Nonalcoholic Fatty Liver Disease ( TREATY-FLD )：a 12-month Follow-up Study

Completed NA Last updated 6 April 2022

What this trial tests

NA trial testing Time restricted feeding in Nonalcoholic Fatty Liver Disease in 88 participants. Completed in 30 December 2021.

Timeline

30 July 2021

Primary endpoint
30 December 2021

30 December 2021

Quick facts

Lead sponsor	Nanfang Hospital, Southern Medical University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	88
Start date	30 July 2021
Primary completion	30 December 2021
Estimated completion	30 December 2021
Sites	1 location across China

Drugs / interventions tested

Time restricted feeding
Continuous Energy Restriction

Conditions studied

Nonalcoholic Fatty Liver Disease — all drugs for Nonalcoholic Fatty Liver Disease →

Sponsor

Nanfang Hospital, Southern Medical University

Who can join

Adults 18 to 75, any sex, with Nonalcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Time restricted feeding (TRF) is a novel type of intermittent calorie restriction diet that involves eating a daily period of 8 hours or less. This is a 6-month follow-up study of TREATY-FLD trial to evaluate the effect of time restricted feeding (TRF) on hepatic fat contents and cardiometabolic risk factors in obese adults over 6 months compared to continuous energy restriction (CER).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of Time-Restricted Eating on Nonalcoholic Fatty Liver Disease: The TREATY-FLD Randomized Clinical Trial.
Wei X, Lin B, Huang Y, Yang S, et al · · 2023 · cited 88× · PMID 36930148 · DOI 10.1001/jamanetworkopen.2023.3513

Verify or expand the search:

Other trials of Time restricted feeding

Trials testing the same drug.

NCT05038137 — Time Restricted Eating on Cancer Risk · NA · completed
NCT05593939 — Slow Age: Interventions to Slow Aging in Humans · Phase 2 · completed
NCT05756868 — The Effect of Time-Restricted Feeding on Anthropometry, Biochemical Parameters, Diet Quality and Eating Behavior · NA · completed
NCT05717127 — Metabolic Impact of Intermittent Fasting in Early Type 2 Diabetes · NA · completed
NCT04627688 — Optimization of Diet Before Surgery (OptiSurg) · NA · unknown

Other recruiting trials for Nonalcoholic Fatty Liver Disease

Currently open trials in the same condition.

NCT07237750 — iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss · NA · recruiting
NCT07093346 — The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patient · NA · recruiting
NCT07248371 — Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases · recruiting
NCT07149571 — To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status · recruiting
NCT06368882 — Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty · Phase 4 · recruiting

Other Nanfang Hospital, Southern Medical University trials

Trials by the same sponsor.

NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04988230 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
Last refreshed: 6 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04988230.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing